Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND ® artificial intelligence (AI) and data mining platform to ...
Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer with limited treatment options and a high probability of recurrence. Tumor growth and relapse of TNBC are ...
(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...
New research led by Murdoch Children’s Research Institute and Federation University Australia reveals how gamma delta T cells develop and produce an immune response. Researchers uncovered the role the ...
ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of ...
IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing significant ...
Researchers have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy. Researchers at ...
Common conditions such as indigestion and heartburn as well as peptic ulcers, autoimmune gastritis and stomach and esophageal cancers have one thing in common – they involve disruptions of the normal ...
Henry Thomas Sampson Jr. was a Black American engineer, inventor and film historian who created the gamma-electric cell in 1971 – a device with the main goal of generating auxiliary power from the ...
Roswell Park scientists show that IL-36γ–armored CAR T cells reprogram neutrophils to trigger powerful immune responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback